Kalaris Therapeutics Inc
KLRSAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
| Date | Firm | Analyst | Target | Price Then | Source |
|---|---|---|---|---|---|
| May 14, 2026 | Wedbush | $17.00(+252%) | $4.83 | TheFly | |
| Apr 16, 2026 | Morgan Stanley | $14.00(+139%) | $5.87 | TheFly | |
| Mar 9, 2026 | Raymond James | Chris Raymond | $23.00(+142%) | $9.51 | StreetInsider |
| Dec 23, 2025 | Chardan Capital | $19.00(+89%) | $10.06 | TheFly | |
| Jul 23, 2025 | Piper Sandler | Biren Amin | $3.00(+17%) | $2.57 | TheFly |
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| Citizens | maintain | Market Outperform | May 13, 2026 |
Earnings History
Next report: Nov 11, 2026 · EPS est. $-0.52| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Aug 11, 2026 | $-0.48 | $-0.49 | — | — |
| May 12, 2026 | $-0.46 | $-0.52 | — | — |
| Mar 17, 2026 | $-0.44 | $-0.56 | — | — |
| Nov 12, 2025 | $-0.64 | $-0.66 | — | — |
| Aug 13, 2025 | $-0.61 | $-0.51 | — | — |
| May 14, 2025 | $-2.52 | $-0.78 | — | — |
| Mar 7, 2025 | $-3.64 | $-2.76 | — | — |
| Nov 12, 2024 | $-0.04 | $-0.14 | — | — |
News
Kalaris Therapeutics Inc. (NASDAQ: KLRS - Get Free Report) has been given an average recommendation of "Moderate Buy" by the seven brokerages that are covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell rating and six have issued a buy rating on the company. The average 1 year target price
BERKELEY HEIGHTS, N.J., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (Nasdaq: KLRS) (“Kalaris”), a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent retinal diseases, today announced that management will participate in a Fireside Chat at the upcoming Morgan Stanley 24th Annual Global Healthcare Conference. Kalaris is currently developing TH103, a dual-action anti-VEGF therapeutic, in a Phase 1b/2 multiple ascen…
Patient dosing is ongoing in the Phase 1b/2 study of TH103; preliminary data anticipated in 1H 2027 Potential Phase 3 clinical trials remain on track for initiation by year-end 2027 $93.5 million in cash, cash equivalents and marketable securities as of June 30, 2026 is expected to fund operations into the fourth quarter of 2027 and through key clinical milestones BERKELEY HEIGHTS, N.J., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (Nasdaq: KLRS) (“Kalaris”), a clinical stage bio…